He characterized the guidance as prudent given the company is “building off of a whole new base” after a stronger finish to the year, saying AxoGen wants to prove performance in new quarters and a new year while maintaining confidence that the underlying business models are elastic.Discussing the company’s 2026 outlook, management framed its guidance of at least 18% top-line growth as reflecting early-stage market penetration across multiple areas, including emergent trauma extremities and elective procedur ...